

**Supplementary Fig S1:** Body weight curves of mice treated with 3-BrPA. **(A)** Mice treated with 3-BrPA by gavage. **(B)** Mice treated with 3-BrPA by aerosol. Body weight was monitored weekly during the treatment duration. No significant difference in body weight was observed in either treatment protocol.

**Supplementary Fig S2:** Differential liver toxicity in aerosol and gavage 3-BrPA liver toxicity experiment. **(A, B, C, D)** Representative Liver histology (hematoxylin and eosin stained, zinc-formalin-fixed, paraffin-embedded liver sections) from the control gavage **(A)**, 10 mg/ml 3-BrPA-treated aerosol **(B)** and 60 mg/kg bw 3-BrPA-treated gavage **(C, D)** group. Livers from aerosol-treated mice showed minimal-to-absent histological change relative to controls **(A)**. The 3-BrPA-treated gavage groups showed a moderate increase in lymphohistiocytic aggregates **(C, arrow)** as well as increased hepatocellular mitotic activity **(D, arrows)**, consistent with mild, reversible liver injury.

**Supplementary Fig S3:** Differential liver toxicity in aerosol and gavage 3-BrPA in 20-weeks chemopreventive experiment. **(A, B, C)** Representative Liver histology from the control gavage **(C)**, 10 mg/ml 3-BrPA-treated aerosol **(B)** and 20 mg/kg bw 3-BrPA-treated gavage **(C)** group.